Do analysts prefer SRNE or ADTX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sorrento Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Aditxt 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend ADTX or AMPE?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aditxt 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Ampio Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger earnings and valuation, ADTX or AMPE?

Ampio Pharmaceuticals is trading at a lower price-to-earnings ratio than Aditxt, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aditxt N/A N/A -$41.71M -$100.79 thousand N/A Ampio Pharmaceuticals N/A N/A -$8.63M -$11.01 N/A

Do analysts prefer PTPI or ADTX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Petros Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Aditxt 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate VINC or ADTX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vincerx Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Aditxt 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, VINC or ADTX?

Vincerx Pharma is trading at a lower price-to-earnings ratio than Aditxt, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vincerx Pharma N/A N/A -$40.16M -$5.31 N/A Aditxt N/A N/A -$41.71M -$100.79 thousand N/A

Is VINC or ADTX more profitable?

Vincerx Pharma has a net margin of 0.00% compared to Aditxt's net margin of -360,152.50%. Vincerx Pharma's return on equity of -248.33% beat Aditxt's return on equity. Company Net Margins Return on Equity Return on Assets Vincerx Pharma N/A -248.33% -132.73% Aditxt -360,152.50% -374.60% -105.93%

Do analysts prefer ADTX or SCPS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aditxt 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Scopus BioPharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better earnings and valuation, ADTX or SCPS?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aditxt N/A N/A -$41.71M -$100.79 thousand N/A Scopus BioPharma N/A N/A -$11.61M N/A N/A

Does the media prefer ADTX or SCPS?

In the previous week, Aditxt had 8 more articles in the media than Scopus BioPharma. MarketBeat recorded 9 mentions for Aditxt and 1 mentions for Scopus BioPharma. Aditxt's average media sentiment score of 0.80 beat Scopus BioPharma's score of 0.00 indicating that Aditxt is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aditxt 2 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Scopus BioPharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Aditxt (ADTX) Competitors

$0.01 -0.01 (-29.73%)

Closing price 04:00 PM Eastern

Extended Trading

$0.02 +0.00 (+17.69%)

As of 07:59 PM Eastern

Compare

ADTX vs. SRNE, AMPE, PTPI, VINC, and SCPS

Should you buy Aditxt stock or one of its competitors? MarketBeat compares Aditxt with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Aditxt include Sorrento Therapeutics (SRNE), Ampio Pharmaceuticals (AMPE), Petros Pharmaceuticals (PTPI), Vincerx Pharma (VINC), and Scopus BioPharma (SCPS). These companies are all part of the "pharmaceutical products" industry.

How does Aditxt compare to Sorrento Therapeutics?

Sorrento Therapeutics (NASDAQ:SRNE) and Aditxt (NASDAQ:ADTX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations.

Sorrento Therapeutics has a net margin of 0.00% compared to Aditxt's net margin of -360,152.50%. Sorrento Therapeutics' return on equity of 0.00% beat Aditxt's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sorrento Therapeutics	N/A	N/A	N/A
Aditxt	-360,152.50%	-374.60%	-105.93%

0.0% of Sorrento Therapeutics shares are held by institutional investors. Comparatively, 15.5% of Aditxt shares are held by institutional investors. 2.6% of Sorrento Therapeutics shares are held by insiders. Comparatively, 0.0% of Aditxt shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Aditxt had 9 more articles in the media than Sorrento Therapeutics. MarketBeat recorded 9 mentions for Aditxt and 0 mentions for Sorrento Therapeutics. Aditxt's average media sentiment score of 0.80 beat Sorrento Therapeutics' score of 0.00 indicating that Aditxt is being referred to more favorably in the news media.

Company	Overall Sentiment
Sorrento Therapeutics	Neutral
Aditxt	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sorrento Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Aditxt	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Aditxt has lower revenue, but higher earnings than Sorrento Therapeutics. Sorrento Therapeutics is trading at a lower price-to-earnings ratio than Aditxt, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sorrento Therapeutics	$60.32M	0.01	-$572.84M	-$0.43	N/A
Aditxt	N/A	N/A	-$41.71M	-$100.79 thousand	N/A

Sorrento Therapeutics has a beta of 0.17, suggesting that its share price is 83% less volatile than the broader market. Comparatively, Aditxt has a beta of 0.84, suggesting that its share price is 16% less volatile than the broader market.

Summary

Aditxt beats Sorrento Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Aditxt compare to Ampio Pharmaceuticals?

Aditxt (NASDAQ:ADTX) and Ampio Pharmaceuticals (NYSE:AMPE) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, media sentiment, institutional ownership and risk.

Aditxt has a beta of 0.84, indicating that its stock price is 16% less volatile than the broader market. Comparatively, Ampio Pharmaceuticals has a beta of 5.96, indicating that its stock price is 496% more volatile than the broader market.

15.5% of Aditxt shares are held by institutional investors. Comparatively, 5.7% of Ampio Pharmaceuticals shares are held by institutional investors. 0.0% of Aditxt shares are held by company insiders. Comparatively, 3.3% of Ampio Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Ampio Pharmaceuticals is trading at a lower price-to-earnings ratio than Aditxt, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aditxt	N/A	N/A	-$41.71M	-$100.79 thousand	N/A
Ampio Pharmaceuticals	N/A	N/A	-$8.63M	-$11.01	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aditxt	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Ampio Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Ampio Pharmaceuticals has a net margin of 0.00% compared to Aditxt's net margin of -360,152.50%. Ampio Pharmaceuticals' return on equity of 0.00% beat Aditxt's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aditxt	-360,152.50%	-374.60%	-105.93%
Ampio Pharmaceuticals	N/A	N/A	N/A

In the previous week, Aditxt had 9 more articles in the media than Ampio Pharmaceuticals. MarketBeat recorded 9 mentions for Aditxt and 0 mentions for Ampio Pharmaceuticals. Aditxt's average media sentiment score of 0.80 beat Ampio Pharmaceuticals' score of 0.00 indicating that Aditxt is being referred to more favorably in the media.

Company	Overall Sentiment
Aditxt	Positive
Ampio Pharmaceuticals	Neutral

Summary

Ampio Pharmaceuticals beats Aditxt on 7 of the 12 factors compared between the two stocks.

How does Aditxt compare to Petros Pharmaceuticals?

Petros Pharmaceuticals (NASDAQ:PTPI) and Aditxt (NASDAQ:ADTX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, analyst recommendations, institutional ownership, media sentiment, valuation, earnings and profitability.

Petros Pharmaceuticals has a beta of 1.86, indicating that its stock price is 86% more volatile than the broader market. Comparatively, Aditxt has a beta of 0.84, indicating that its stock price is 16% less volatile than the broader market.

Petros Pharmaceuticals has higher revenue and earnings than Aditxt. Petros Pharmaceuticals is trading at a lower price-to-earnings ratio than Aditxt, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Petros Pharmaceuticals	$5.11M	0.04	-$8.16M	-$1.64	N/A
Aditxt	N/A	N/A	-$41.71M	-$100.79 thousand	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Petros Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Aditxt	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Aditxt had 9 more articles in the media than Petros Pharmaceuticals. MarketBeat recorded 9 mentions for Aditxt and 0 mentions for Petros Pharmaceuticals. Aditxt's average media sentiment score of 0.80 beat Petros Pharmaceuticals' score of 0.00 indicating that Aditxt is being referred to more favorably in the news media.

Company	Overall Sentiment
Petros Pharmaceuticals	Neutral
Aditxt	Positive

Petros Pharmaceuticals has a net margin of 0.00% compared to Aditxt's net margin of -360,152.50%. Petros Pharmaceuticals' return on equity of -78.22% beat Aditxt's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Petros Pharmaceuticals	N/A	-78.22%	-23.50%
Aditxt	-360,152.50%	-374.60%	-105.93%

12.3% of Petros Pharmaceuticals shares are held by institutional investors. Comparatively, 15.5% of Aditxt shares are held by institutional investors. 12.3% of Petros Pharmaceuticals shares are held by company insiders. Comparatively, 0.0% of Aditxt shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Petros Pharmaceuticals beats Aditxt on 8 of the 13 factors compared between the two stocks.

How does Aditxt compare to Vincerx Pharma?

Vincerx Pharma (NASDAQ:VINC) and Aditxt (NASDAQ:ADTX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, profitability, earnings, institutional ownership, analyst recommendations, valuation, dividends and media sentiment.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vincerx Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Aditxt	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Vincerx Pharma has a beta of 1.46, suggesting that its stock price is 46% more volatile than the broader market. Comparatively, Aditxt has a beta of 0.84, suggesting that its stock price is 16% less volatile than the broader market.

44.0% of Vincerx Pharma shares are owned by institutional investors. Comparatively, 15.5% of Aditxt shares are owned by institutional investors. 15.6% of Vincerx Pharma shares are owned by company insiders. Comparatively, 0.0% of Aditxt shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Aditxt had 9 more articles in the media than Vincerx Pharma. MarketBeat recorded 9 mentions for Aditxt and 0 mentions for Vincerx Pharma. Aditxt's average media sentiment score of 0.80 beat Vincerx Pharma's score of 0.00 indicating that Aditxt is being referred to more favorably in the news media.

Company	Overall Sentiment
Vincerx Pharma	Neutral
Aditxt	Positive

Vincerx Pharma has a net margin of 0.00% compared to Aditxt's net margin of -360,152.50%. Vincerx Pharma's return on equity of -248.33% beat Aditxt's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vincerx Pharma	N/A	-248.33%	-132.73%
Aditxt	-360,152.50%	-374.60%	-105.93%

Vincerx Pharma is trading at a lower price-to-earnings ratio than Aditxt, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vincerx Pharma	N/A	N/A	-$40.16M	-$5.31	N/A
Aditxt	N/A	N/A	-$41.71M	-$100.79 thousand	N/A

Summary

Vincerx Pharma beats Aditxt on 7 of the 12 factors compared between the two stocks.

How does Aditxt compare to Scopus BioPharma?

Aditxt (NASDAQ:ADTX) and Scopus BioPharma (NASDAQ:SCPS) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, media sentiment, valuation, institutional ownership, earnings and dividends.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aditxt	N/A	N/A	-$41.71M	-$100.79 thousand	N/A
Scopus BioPharma	N/A	N/A	-$11.61M	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aditxt	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Scopus BioPharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

15.5% of Aditxt shares are owned by institutional investors. 0.0% of Aditxt shares are owned by insiders. Comparatively, 5.1% of Scopus BioPharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Aditxt had 8 more articles in the media than Scopus BioPharma. MarketBeat recorded 9 mentions for Aditxt and 1 mentions for Scopus BioPharma. Aditxt's average media sentiment score of 0.80 beat Scopus BioPharma's score of 0.00 indicating that Aditxt is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aditxt	2 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Scopus BioPharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Aditxt has a beta of 0.84, indicating that its share price is 16% less volatile than the broader market. Comparatively, Scopus BioPharma has a beta of -0.14, indicating that its share price is 114% less volatile than the broader market.

Scopus BioPharma has a net margin of 0.00% compared to Aditxt's net margin of -360,152.50%. Scopus BioPharma's return on equity of 0.00% beat Aditxt's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aditxt	-360,152.50%	-374.60%	-105.93%
Scopus BioPharma	N/A	N/A	N/A

Summary

Aditxt and Scopus BioPharma tied by winning 5 of the 10 factors compared between the two stocks.

Get Aditxt News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ADTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ADTX vs. The Competition

Export

Metric	Aditxt	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$20K	$2.95B	$6.47B	$11.73B
Dividend Yield	N/A	1.78%	2.67%	5.56%
P/E Ratio	0.00	18.14	24.43	24.09
Price / Sales	N/A	294.59	503.66	108.37
Price / Cash	N/A	56.09	43.20	54.62
Price / Book	0.00	4.00	10.50	6.82
Net Income	-$41.71M	$75.85M	$3.56B	$337.41M
7 Day Performance	N/A	-1.99%	-2.02%	-0.96%
1 Month Performance	N/A	-3.48%	0.66%	1.68%
1 Year Performance	N/A	18.26%	21.85%	26.88%

Aditxt Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ADTX Aditxt	1.0388 of 5 stars	$0.01 -29.7%	N/A	-100.0%	$20K	N/A	N/A	60	News Coverage Gap Down High Trading Volume
SRNE Sorrento Therapeutics	N/A	$0.00 flat	N/A	-52.4%	$276K	$60.32M	N/A	800	Gap Up
AMPE Ampio Pharmaceuticals	N/A	$0.18 flat	N/A	N/A	$208K	N/A	N/A	20
PTPI Petros Pharmaceuticals	N/A	$0.01 flat	N/A	-74.9%	$190K	$5.11M	N/A	20	Gap Up
VINC Vincerx Pharma	N/A	$0.01 +1.6%	N/A	-74.8%	$68K	N/A	N/A	60

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ADTX) was last updated on 6/11/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aditxt (ADTX) Competitors

ADTX vs. SRNE, AMPE, PTPI, VINC, and SCPS

How does Aditxt compare to Sorrento Therapeutics?

Summary

How does Aditxt compare to Ampio Pharmaceuticals?

Summary

How does Aditxt compare to Petros Pharmaceuticals?

Summary

How does Aditxt compare to Vincerx Pharma?

Summary

How does Aditxt compare to Scopus BioPharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADTX vs. The Competition

Aditxt Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aditxt (ADTX) Competitors

ADTX vs. SRNE, AMPE, PTPI, VINC, and SCPS

How does Aditxt compare to Sorrento Therapeutics?

Is SRNE or ADTX more profitable?

Do insiders and institutionals believe in SRNE or ADTX?

Does the media refer more to SRNE or ADTX?

Do analysts prefer SRNE or ADTX?

Which has higher earnings & valuation, SRNE or ADTX?

Which has more volatility and risk, SRNE or ADTX?

Summary

How does Aditxt compare to Ampio Pharmaceuticals?

Which has more volatility and risk, ADTX or AMPE?

Do insiders & institutionals hold more shares of ADTX or AMPE?

Which has stronger earnings and valuation, ADTX or AMPE?

Do analysts recommend ADTX or AMPE?

Is ADTX or AMPE more profitable?

Does the media prefer ADTX or AMPE?

Summary

How does Aditxt compare to Petros Pharmaceuticals?

Which has more volatility and risk, PTPI or ADTX?

Which has preferable earnings & valuation, PTPI or ADTX?

Do analysts prefer PTPI or ADTX?

Does the media refer more to PTPI or ADTX?

Is PTPI or ADTX more profitable?

Do insiders and institutionals have more ownership in PTPI or ADTX?

Summary

How does Aditxt compare to Vincerx Pharma?

Do analysts rate VINC or ADTX?

Which has more volatility & risk, VINC or ADTX?

Do insiders & institutionals believe in VINC or ADTX?

Does the media refer more to VINC or ADTX?

Is VINC or ADTX more profitable?

Which has better earnings and valuation, VINC or ADTX?

Summary

How does Aditxt compare to Scopus BioPharma?

Which has better earnings and valuation, ADTX or SCPS?

Do analysts prefer ADTX or SCPS?

Do institutionals and insiders hold more shares of ADTX or SCPS?

Does the media prefer ADTX or SCPS?

Which has more volatility and risk, ADTX or SCPS?

Is ADTX or SCPS more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADTX vs. The Competition

Aditxt Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools